Nicotine In Cigarettes And Smokeless Tobacco Products Is A Drug And These Products Are Nicotine Delivery Devices And Under The Federal Food Drug And Cosmetic Act Appendices

Includes: background on nicotine pharmacology; corporate relationship between British-American Tobacco Co. and Brown and Williamson Tobacco Co.; FDA letters to tobacco manufacturers; bibliography of industry-funded research; marketing of cigarettes and smokeless tobacco in the U.S.; citizen petitions and submitted comments; statements by David A. Kessler, M.D., Commissioner of Food and Drugs, on nicotine-containing cigarettes and on the control and manipulation of nicotine in cigarettes; and remarks by David A. Kessler, M.D., The Samuel Rubin Program, The Columbia University School of Law, March 8, 1995.

Millions of Americans use e-cigarettes. Despite their popularity, little is known about their health effects. Some suggest that e-cigarettes likely confer lower risk compared to combustible tobacco cigarettes, because they do not expose users to toxicants produced through combustion. Proponents of e-cigarette use also tout the potential benefits of e-cigarettes as devices that could help combustible tobacco cigarette smokers to quit and thereby reduce tobacco-related health risks. Others are concerned about the exposure to potentially toxic substances contained in e-cigarette emissions, especially in individuals who have never used tobacco products such as youth and young adults. Given their relatively recent introduction, there has been little time for a scientific body of evidence to develop on the health effects of e-cigarettes. Public Health Consequences of E-Cigarettes reviews and critically assesses the state of the emerging evidence about e-cigarettes and health. This report makes recommendations for the improvement of this research and highlights gaps that are a priority for future research.